Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | FAAH | O00519 | 2/20 | 0.84 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | ADH1B | P00325 | 1/20 | 0.55 |
| ▸ | ADH1C | P00326 | 1/20 | 0.55 |
| ▸ | ADH1A | P07327 | 1/20 | 0.55 |
| ▸ | ADH4 | P08319 | 1/20 | 0.55 |
| ▸ | ADH7 | P40394 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nonanal SCHEMBL1697203 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL371426 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL154928 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Undecanal SCHEMBL1871746 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL3118926 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL3190497 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Decanal SCHEMBL10857921 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL371480 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Tetradecanal SCHEMBL10857929 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL15136035 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110283223-B | Cationic lipid molecule and application thereof in nucleic acid delivery | 广州市锐博生物科技有限公司 | 2022-01-04 | — | — | CN | claimed |
| US-20080044462-A1 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | COLLEGIUM PHARMACEUTICAL, INC. DELAWARE | 2008-02-21 | — | — | US | claimed |
| WO-2007117581-A2 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20070116757-A1 | Methylene Blue Derivatives | COLLEGIUM PHARMACEUTICAL, INC. | 2007-05-24 | — | — | US | claimed |
| WO-2007056439-A1 | SALTS OF METHYLENE BLUE AND ITS DERIVATIVES | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| CN-1791391-A | Composition and food and drink containing higher fatty acid derivative | EISAI CO LTD (JP) | 2006-06-21 | — | — | CN | claimed |
| WO-1999010359-A2 | LIPOSOMIC BASED SIALYL LEWIS X MIMETICS | NOVARTIS AG (CH) | 1999-03-04 | — | — | WO | claimed |
| EP-0688555-A2 | Hair-growing agent | TANABE SEIYAKU CO., LTD. (JP) | 1995-12-27 | — | — | EP | claimed |
| EP-4591884-A1 | LIPID COMPOUND FOR NUCLEIC ACID DELIVERY, AND RELATED USE AND MEDICAMENT COMPRISING SAME | Beijing Baishihekang Pharmaceutical Technology (Bsjpharma) Co., Ltd. (CN) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025096734-A1 | MICROCAPSULES | FMC CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4063560-B1 | MULTI-STEP PROCESS FOR THE ISOLATION OF COMPONENTS FROM MISCANTHUS | EXEGI IP MAN B V (NL) | 2024-02-07 | — | — | EP | disclosed |
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | NIPPON SHOKUBAI CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| WO-2023238837-A1 | EXOSOME COMPLEX AND MANUFACTURING METHOD THEREOF | JSR株式会社 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023238859-A1 | COATED PARTICLES FOR COSMETIC | 三洋化成工業株式会社 | 2023-12-14 | — | — | WO | disclosed |
| EP-0604945-A1 | TAN-1511, its derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0517262-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-09 | — | — | EP | disclosed |
| EP-0503508-A1 | Vesicles and polymeric vesicles | Kao Corporation (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0094804-B1 | GLUCOSAMINYL MURAMYL PEPTIDE DERIVATIVES | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-11-13 | — | — | EP | disclosed |
| US-4545932-A | NONSPECIFIC RESISTANCE TO MICROBIAL INFECTIONS, IMMUNOSTIMULANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1985-10-08 | — | — | US | disclosed |
| EP-0094804-A1 | Glucosaminyl muramyl peptide derivatives | Dainippon Pharmaceutical Co., Ltd. (JP) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | PLIN5, PHOSPHO1, PLIN3 | TSHR 1575/4885FAAH 94/4885TRPV1 825/4885 |
| US-20070116757-A1 | Methylene Blue Derivatives | ACMSD, SI, HTR2B | TSHR 4306/4885FAAH 412/4885TRPV1 300/4885 |
| US-20080044462-A1 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | BDNF, FFAR4, FFAR2 | TSHR 1885/4885FAAH 126/4885TRPV1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.